Retraction Note to: Anti-Fracture Efficacy of Risedronic Acid in Men

A Meta-Analysis of Randomized Controlled Trials

Zhao-Ming Zhong¹ · Jian-Ting Chen¹

Published online: 28 January 2021
© Springer Nature Switzerland AG 2021

Retraction to: Clin Drug Invest (2009) 29(5):349–357
<https://doi.org/10.2165/00044011-200929050-00007>

The authors have retracted this article because since its publication two [1, 2] of the four studies included in the meta-analysis (cited as references 13 and 14 in the article) have been retracted. The results of this meta-analysis are therefore invalid. Both authors agree with this retraction.

References

1. Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. *Neurology*. 2007;68:911–5.
2. Sato Y, Iwamoto J, Kanoko T, et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. *Arch Intern Med*. 2005;165:1743–8.

The original article can be found online at <https://doi.org/10.2165/00044011-200929050-00007>.

✉ Jian-Ting Chen
chenjt99@tom.com

¹ Department of Orthopedic and Spinal Surgery,
Nanfang Hospital, Southern Medical University,
1838 North Guangzhou Avenue, Guangzhou 510515,
People's Republic of China